ask our doctors

Lymphoma Cutaneous T Cell

Get the facts on Lymphoma Cutaneous T Cell treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Lymphoma Cutaneous T Cell prevention, screening, research, statistics and other Lymphoma Cutaneous T Cell related topics. We answer all your qestions about Lymphoma Cutaneous T Cell.

Question: Can I donate bone marrow with a history of cutaneous lymphoma? I had cutaneous T-cell lymphoma earlier this year and am now cancer-free. It was confined to a tumor on my arm with no lymph node or organ involvement. I was wondering if I could still be a bone marrow donor?

Answer: I don't think you can. They're pretty picky when it comes to a history of cancer, especially a blood cancer like Lymphoma. Here is the bit from the National Registry: http://www.marrow.org/JOIN/Med_Guideline… I'd love to donate blood or marrow, but I never can and that really does upset me. I'd love to help someone else, considering a stranger helped save me.


Lymphoma Cutaneous T Cell News

Bradenton Herald

Seattle Genetics Rises on Positive Trial Data: Seattle Mover
BusinessWeek
 

Proactive Investors USA & Canada

Allos Unveils Encouraging Activity In Phase 1 Study Of Folotyn Plus Bexarotene
NASDAQ
 

Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and ...

PipelineReview.com (press release)
SAN FRANCISCO, CA, USA I January 26, 2012 I Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma ...
 

Ceptaris cutaneous T-cell lymphoma drug gets Europe orphan status

Philadelphia Business Journal
The European Medicines Agency granted orphan drug designation to Ceptaris' experimental cancer therapy, mechlorethamine gel, which is being developed as a potential treatment of cutaneous t-Cell lymphoma. Orphan drug designation is granted to promote ...
 

Biotech Stocks To Watch In 2012

Seeking Alpha
Adcetris had a response rate of 65% in 17 patients with cutaneous T cell lymphoma (CTCL), an indication for which Celgene's Istodax was approved based on a 34% response rate. Investigators also reported 2 case studies of heavily pretreated PTCL ...
 

A leukemia drug kills cancerous T-cells while sparing normal immunity

Medical Xpress
Leukemic cutaneous T-cell lymphoma (L-CTCL) is a leukemia arising from T-cells, a type of white blood cell. This cancer can involve the skin and other organs, and patients often die within three years. Rachael A. Clark, MD, PhD, BWH assistant professor ...
 

New combination treatment more effective in treating cutaneous T-Cell lymphoma

News-Medical.net
The article outlines findings from a first-of-its-kind study showing that O6-benzylguanine is successful in treating cutaneous T-Cell lymphoma by enhancing the efficacy of topical chemotherapy (carmustine). "Current therapy for cutaneous T-Cell ...
 

Novel treatment for skin lymphoma

Medical Xpress
The article outlines findings from a first-of-its-kind study showing that O6-benzylguanine is successful in treating cutaneous T-Cell lymphoma by enhancing the efficacy of topical chemotherapy (carmustine). "Current therapy for cutaneous T-Cell ...
 

Proactive Investors USA & Canada

OncoSec Medical looks to three phase 2 trials in 2012
Proactive Investors USA & Canada
 

OncoSec Medical's President And CEO Lists His Firm's 2012 Milestones

Seeking Alpha
OncoSec is currently initiating three Phase 2 clinical trials in metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. All three of these trials are being held under a physician Investigational New Drug application.